Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, October 11th.
Ampio Pharmaceuticals (NYSEMKT:AMPE) opened at 1.09 on Wednesday. Ampio Pharmaceuticals has a 12-month low of $0.38 and a 12-month high of $1.34. The stock’s 50 day moving average is $0.72 and its 200 day moving average is $0.63. The stock’s market capitalization is $74.37 million.
COPYRIGHT VIOLATION WARNING: This article was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.truebluetribune.com/2017/10/23/ampio-pharmaceuticals-inc-ampe-raised-to-sell-at-valuengine.html.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ampio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.